1/ Shortish thread about FGF21, a hormone secreted by the liver, muscles and other tissues that is profoundly interesting.
👉 Regulates lipids (HDL, LDL, LPL, ApoCIII and more)
👉 FGF21 analogs are being explored as a treatment for obesity, type II diabetes, NAFLD
2/ FGF21 really caught my attention when I read this paper, which provides compelling evidence that FGF21 is essential for in ketosis and lipid oxidation in mice on a ketogenic diet. cell.com/cell-metabolis…
3/ Ketogenic diet increased GF21 levels ~20-fold and knockdown of FGF21 created severe metabolic impairments including decreased ketones, hypertriglyceridemia, fatty liver, and decreased expression of ton of genes involved in lipid and ketone metabolism
4/ The axis of activity seems to be:
Increased lipolysis➡️ NEFA➡️activation of PPARalpha transcription factor➡️ induction of FGF21 ➡️ regulation of genes involved in ketosis and lipid metabolism
In effect, FGF21 may be one of the key signals regulating fat adaptation
5/ There is now energized debate over wether #obesity represents "FGF21 resistant state", analogous to insulin resistance (and FGF21 levels are associated w/ BMI, TG, and HOMA-IR/Matsuda index)
6/ There is also interest in exploring FGF21 analogs and pathway activators as a treatment for type 2 diabetes, obesity, and NAFLD nature.com/articles/s4157…
2/ Study used Mendelian randomization 2assess possible effects of SPECIFIC pharmacological CETP or PCSK9 lowering on risk
Useful for assessing whether the failures of CETP inhibitors are more likely due to off-target or on-target effects and for directing future development...
3/ Some positive things:
👉MR analysis suggests CEPT inhibition could be useful4reducing coronary hard disease risk (OR=0.95) risk & thus further drug development may be warranted
👉CEPTi anacetrapib&evacetrapib most closely
reflected the on-target association of lower CETP...
1/ Time for another monster thread aimed at adding a bit of nuance to Twitter. This one is about Lean Mass Hyper-Responders, HDL, and it's topic might surprise you: Is ⬆️HDL-C in #LMHR bad? Read on to have thoughts provoked...
2/ Something I have intentionally yet to point out (but plan to include in upcoming writings) regards the potential adverse effects of high HDL-C in #LMHR? What?! High HDL is bad? Well, based on the epidemiology, yes. Multiple studies...
3/ including Copenhagen City Heart and CANHEART, report a U-shaped mortality curve whereby very low or very high HDL levels are associated with increased mortality. The most striking example is the blue line, which is all-cause mortality in CANHEART.
1/ It's been quite a week on Twitter regarding #lowcarb and LDL
I have been on the fence about weighing in, not wanting to add to the dog pile, but decided 2drop my thoughts in this thread
If u don't have time to READ THE WHOLE THING IN CONEXT, ignore& consider me🪰 on the wall
2/ I'll first address @deirdre_tobias analysis of LDL and all cause mortality. With the caveats that I'm not an epidemiologist &hope to have more insightful questions when time passes and the dust settles, I am not in disagreement w/ the main results: high LDL associated with ACM
3/ That's actually old news, isn't it?Not so say that the analysis doesn't bring something to the table, but on a population level v high LDL levels (will get to low LDL in a minute) are generally undesirable. Thus, all things being =, a conservative gambler would pick low-is LDL
2/ Points 1 and 2 go in line with what I'd expect. Leaner metabolically healthy people probably have greater metabolic flexibility, resulting in better shift to fat burning. But point 3 about AMPK surprised me. Here's why...
3/AMPK is the cellular energy sensor. It's activated, in part by low energy status, i.e.
Decrease cellular energy supply increases AMPK activity
Seems paradoxical that in lean persons who r fasting AMPK activity goes DOWN, not UP, as if there is more energy when taking none in
1/ As a #LMHR and close colleague of @DaveKeto I feel compelled to jump in here and clarify my own stance on LDLp and ASCVD risk because I feel that our positions are usually misrepresented by others. Here we go…
2/ To cut to the chase, outside the low-carb lipid triad of high LDL and High HDL and low TG, I would absolutely personally consider elevated LDLp an issue. Where I to have high LDL and atherogenic dyslipidemia I would both take an LDL lowering med and, more importantly IMO…
3/ change my lifestyle to improve the atherogenic dyslipedmia. Personally I do have concerns about longterm safety use of statins specifically and would preference Zetia/PCSK9i. But that’s besides the point. I won’t speak for @DaveKeto but for my part the LMHR phenomenon & LEM…